Skip to main content
. Author manuscript; available in PMC: 2014 Feb 25.
Published in final edited form as: Clin Cancer Res. 2010 Oct 6;16(22):5564–5572. doi: 10.1158/1078-0432.CCR-10-1233

Table 4.

Antitumor activity in evaluable patients (n = 16)

Best response No. patients Tumor types Reduction
Partial response 4 Breast Complete response in liver; stable disease in bone
Stomach ↓32% in lymph nodes
Gastroesophageal
Ocular melanoma
Minor response 3 Mesothelioma ↓23% in lymph nodes
Prostate ↓30% in PSA
SCC H + N ↓26% in lymph node
Stable disease 7 Prostate
Unknown 1°
Melanoma
Esophagus
Pancreas